RISPERIDONE

Post-LOE

risperidone

ANDAORALTABLET
Approved
Dec 2008
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Pharmacologic Class:

Atypical Antipsychotic

Clinical Trials (5)

NCT04418466Phase 1/2Completed

Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant

Started Apr 2021
NCT03978832Phase 4Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

Started Jun 2019
69 enrolled
Schizophrenia
NCT03713658Phase 4Completed

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

Started Oct 2018
34 enrolled
Schizophrenia
NCT03390712N/AUnknown

Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection

Started Jan 2018
328 enrolled
Schizophrenia Spectrum and Other Psychotic Disorders
NCT02758067Phase 3Withdrawn

Comparison of the Effectiveness of Brexpiprazole With That of Risperidone

Started Jun 2016
0
Schizophrenia